Smith Jason Drew

General CounselUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Feb 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$147K
Net Open-Market Flow
-$147K
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2026Sell(S)2K$19.69$32K51K
Feb 3, 2026Sell(S)3K$19.69$52K53K
Feb 3, 2026Sell(S)3K$19.69$63K56K
Jan 31, 2026Option exercise(M)3K59K
Jan 31, 2026Option exercise(M)7K50K
Jan 31, 2026Option exercise(M)6K55K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2026Option exercise(M)7K$00
Jan 31, 2026Option exercise(M)3K$07K
Jan 31, 2026Option exercise(M)6K$06K
Jan 31, 2026Grant(A)33K$033K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-003778) within minutes of acceptance. Every field above traces to the original document. Verify it directly: